person · Reporting owner

SARGEN GREGORY

Disclosed activity across 3 companies

Tapewire entity: 37639
SEC CIK: 0001227835

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Protara Therapeutics, Inc.TARA · Entity 6203	Director	June 15, 2026	June 16, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Protara Therapeutics, Inc.

Report date June 15, 2026 · Filed June 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14	Direct	31,000	Reported balance After 2026-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Filing footnotes · ownership attribution and instrument terms

F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Avid Bioservices, Inc.

Report date February 05, 2025 · Filed February 07, 2025

Section 16 reporting ended · disclosed 2025-02-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2025-02-05 transaction · row 1 1 source row Row 1 · 2025-02-05 · Disposition to issuer · Disposed 36,368 · Balance 0 F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.67 · Expires 2027-11-27	Direct	49,305	Reported balance After 2025-02-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-05 · Disposition to issuer · Disposed 75,000 · Balance 49,305 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.22 · Expires 2025-12-14	Direct	29,705	Reported balance After 2025-02-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-02-05 · Disposition to issuer · Disposed 19,600 · Balance 29,705 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2027-12-14	Direct	0	Reported balance After 2025-02-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-02-05 · Disposition to issuer · Disposed 10,030 · Balance 0 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
Stock Option right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 · Expires 2027-01-09	Direct	10,030	Reported balance After 2025-02-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-02-05 · Disposition to issuer · Disposed 19,675 · Balance 10,030 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2025-02-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-02-05 · Disposition to issuer · Disposed 8,147 · Balance 0 F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub.

F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").

F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.

F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.

F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.

F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement.

CAMBREX CORP

Report date December 04, 2019 · Filed December 05, 2019

Section 16 reporting ended · disclosed 2019-12-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2019-12-04 transaction · row 7 7 source rows · reconciled sequence Row 1 · 2019-12-04 · Exercise / conversion · Acquired 7,500 · Balance 39,925 Row 2 · 2019-12-04 · Exercise / conversion · Acquired 15,000 · Balance 54,925 Row 3 · 2019-12-04 · Exercise / conversion · Acquired 22,500 · Balance 77,425 Row 4 · 2019-12-04 · Exercise / conversion · Acquired 25,000 · Balance 102,425 Row 5 · 2019-12-04 · Exercise / conversion · Acquired 20,000 · Balance 122,425 Row 6 · 2019-12-04 · Grant · Acquired 43,500 · Balance 165,925 F1: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration. Row 7 · 2019-12-04 · Sale · Disposed 165,925 · Balance 0 F2: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.81	Direct	Reported balance After 2019-12-04 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-12-04 · Exercise / conversion · Acquired 7,500 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.36	Direct	Reported balance After 2019-12-04 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-12-04 · Exercise / conversion · Acquired 15,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.65	Direct	Reported balance After 2019-12-04 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-12-04 · Exercise / conversion · Acquired 22,500 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.64	Direct	Reported balance After 2019-12-04 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2019-12-04 · Exercise / conversion · Acquired 25,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.61	Direct	Reported balance After 2019-12-04 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2019-12-04 · Exercise / conversion · Acquired 20,000 · Balance 0 F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration.

F2: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement.

F3: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 15, 2026 Filed Jun 16, 2026 20:05 UTC	Protara Therapeutics, Inc. TARA · Entity 6203	GrantStock Option (Right to Buy) · Derivative	31,000	$0.00 Strike: $3.94	$0.00	Disclosure SEC source: 0001213900-26-069247 · marketforms-73184.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document
June 12, 2025 Filed Jun 13, 2025 20:05 UTC	Protara Therapeutics, Inc. TARA · Entity 6203	GrantStock Option (Right to Buy) · Derivative	24,000	$0.00 Strike: $3.26	$0.00	Disclosure SEC source: 0001213900-25-054286 · marketforms-69816.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerRestricted Stock Units · Derivative	8,147	Not disclosed Strike: $0.00	Not disclosed	Disclosure SEC source: 0001683168-25-000862 · ownership.xml · derivative · entry 6 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,147 shares Expires not disclosed F5 · shares: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6 · price: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. F6 · derivative.exercise_date: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. F6 · derivative.expiration_date: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerStock Option (right to buy) · Derivative	10,030	Not disclosed Strike: $10.72	Not disclosed	Disclosure SEC source: 0001683168-25-000862 · ownership.xml · derivative · entry 5 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,030 shares Expires 2027-12-14 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerStock Option right to buy) · Derivative	19,675	Not disclosed Strike: $6.87	Not disclosed	Disclosure SEC source: 0001683168-25-000862 · ownership.xml · derivative · entry 4 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,030 Underlying: Common Stock · 19,675 shares Expires 2027-01-09 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerStock Option (right to buy) · Derivative	19,600	Not disclosed Strike: $5.22	Not disclosed	Disclosure SEC source: 0001683168-25-000862 · ownership.xml · derivative · entry 3 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,705 Underlying: Common Stock · 19,600 shares Expires 2025-12-14 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerStock Option (right to buy) · Derivative	75,000	Not disclosed Strike: $4.67	Not disclosed	Disclosure SEC source: 0001683168-25-000862 · ownership.xml · derivative · entry 2 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,305 Underlying: Common Stock · 75,000 shares Expires 2027-11-27 F3 · shares: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4 · price: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. F4 · derivative.exercise_date: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. Read SEC document
February 05, 2025 Filed Feb 7, 2025 19:39 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Disposition to issuerCommon Stock, $0.001 par value	36,368	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-25-000862 · ownership.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2 · price: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). Read SEC document
December 14, 2024 Filed Dec 17, 2024 19:49 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	8,147	$0.00	$0.00	Disclosure SEC source: 0001683168-24-008804 · ownership.xml · derivative · entry 3 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,147 Underlying: Common Stock · 8,147 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2024 shall fully vest on December 14, 2025, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document
December 14, 2024 Filed Dec 17, 2024 19:49 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionRestricted Stock Units · Derivative	26,756	$0.00	$0.00	Disclosure SEC source: 0001683168-24-008804 · ownership.xml · derivative · entry 2 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,756 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2023 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2024. Read SEC document
December 14, 2024 Filed Dec 17, 2024 19:49 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionCommon Stock, $0.001 par value	26,756	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-24-008804 · ownership.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document
June 07, 2024 Filed Jun 10, 2024 22:00 UTC	Protara Therapeutics, Inc. TARA · Entity 6203	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $2.67	$0.00	Disclosure SEC source: 0001213900-24-051379 · marketforms-66262.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document
December 14, 2023 Filed Dec 18, 2023 19:33 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	26,756	$0.00	$0.00	Disclosure SEC source: 0001683168-23-008944 · ownership.xml · derivative · entry 3 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,756 Underlying: Common Stock · 26,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2023 shall fully vest on December 14, 2024, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2023 shall fully vest on December 14, 2024, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document
December 14, 2023 Filed Dec 18, 2023 19:33 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionRestricted Stock Units · Derivative	9,612	$0.00	$0.00	Disclosure SEC source: 0001683168-23-008944 · ownership.xml · derivative · entry 2 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2022 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2023. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2022 pursuant to the Issuer's non-employee director compensation program fully vested on December 14, 2023. Read SEC document
December 14, 2023 Filed Dec 18, 2023 19:33 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionCommon Stock, $0.001 par value	9,612	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-23-008944 · ownership.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document
June 07, 2023 Filed Jun 8, 2023 20:10 UTC	Protara Therapeutics, Inc. TARA · Entity 6203	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $2.85	$0.00	Disclosure SEC source: 0001213900-23-047469 · ownership.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document
April 11, 2023 Filed Apr 12, 2023 19:34 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	SaleCommon Stock, $0.001 par value	7,011	$20.24	$141,918.77	Disclosure SEC source: 0001683168-23-002321 · ownership.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $20.09 to $20.33. The Reporting Person has provided to the Issuer, and hereby undertakes to provide the SEC staff or a security holder of the Issuer, upon request, information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
December 14, 2022 Filed Dec 16, 2022 20:01 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	9,612	$0.00	$0.00	Disclosure SEC source: 0001683168-22-008498 · ownership.xml · derivative · entry 3 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,612 Underlying: Common Stock · 9,612 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: The RSUs granted to the reported person on December 14, 2022 shall fully vest on December 14, 2023, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: The RSUs granted to the reported person on December 14, 2022 shall fully vest on December 14, 2023, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document
December 14, 2022 Filed Dec 16, 2022 20:01 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionRestricted Stock Units · Derivative	4,632	$0.00	$0.00	Disclosure SEC source: 0001683168-22-008498 · ownership.xml · derivative · entry 2 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2021 pursuant to the Issuer's non-employee director compensation program which fully vested on December 14, 2022. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2021 pursuant to the Issuer's non-employee director compensation program which fully vested on December 14, 2022. Read SEC document
December 14, 2022 Filed Dec 16, 2022 20:01 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionCommon Stock, $0.001 par value	4,632	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-22-008498 · ownership.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document
June 08, 2022 Filed Jun 9, 2022 20:10 UTC	Protara Therapeutics, Inc. TARA · Entity 6203	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $3.50	$0.00	Disclosure SEC source: 0001213900-22-031992 · ownership.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document
December 14, 2021 Filed Dec 16, 2021 21:34 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	4,632	$0.00	$0.00	Disclosure SEC source: 0001683168-21-006440 · ownership.xml · derivative · entry 3 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,632 Underlying: Common Stock · 4,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F3 · kind: Annual equity award grant pursuant to the Issuer's non-employee director compensation program. F4 · derivative.exercise_date: The RSUs granted to the reporting person shall fully vest on December 14, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. F4 · derivative.expiration_date: The RSUs granted to the reporting person shall fully vest on December 14, 2022, subject to the reporting person's continuous service to the Issuer on such vesting date. Read SEC document
December 14, 2021 Filed Dec 16, 2021 21:34 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionRestricted Stock Units · Derivative	2,379	$0.00	$0.00	Disclosure SEC source: 0001683168-21-006440 · ownership.xml · derivative · entry 2 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,379 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. F2 · derivative.exercise_date: RSUs granted to the reporting person on December 14, 2020 fully vested on December 14, 2021. F2 · derivative.expiration_date: RSUs granted to the reporting person on December 14, 2020 fully vested on December 14, 2021. Read SEC document
December 14, 2021 Filed Dec 16, 2021 21:34 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	Exercise / conversionCommon Stock, $0.001 par balue	2,379	Not disclosed	Not disclosed	Disclosure SEC source: 0001683168-21-006440 · ownership.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting, one share of the Issuer's Common Stock. Read SEC document
June 09, 2021 Filed Jun 11, 2021 00:07 UTC	Protara Therapeutics, Inc. TARA · Entity 6203	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $10.51	$0.00	Disclosure SEC source: 0001209191-21-039685 · doc4.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document
December 14, 2020 Filed Dec 16, 2020 20:00 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantRestricted Stock Units · Derivative	2,379	$0.00	$0.00	Disclosure SEC source: 0001683168-20-004318 · ownership.xml · derivative · entry 2 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,379 Underlying: Common Stock · 2,379 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's Common Stock. F1 · shares: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. F2 · derivative.expiration_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. Read SEC document
December 14, 2020 Filed Dec 16, 2020 20:00 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantStock Option (right to buy) · Derivative	10,030	$0.00 Strike: $10.72	$0.00	Disclosure SEC source: 0001683168-20-004318 · ownership.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,305 Underlying: Common Stock · 10,030 shares Expires 2027-12-14 F1 · shares: Annual grant of equity awards pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: 100% of each equity award granted to the reporting person shall vest on December 14, 2021. Read SEC document
June 09, 2020 Filed Jun 11, 2020 17:42 UTC	Protara Therapeutics, Inc. TARA · Entity 6203	GrantStock Option (Right to Buy) · Derivative	9,000	$0.00 Strike: $35.00	$0.00	Disclosure SEC source: 0001209191-20-035851 · doc4.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document
January 10, 2020 Filed Jan 14, 2020 00:20 UTC	Protara Therapeutics, Inc. TARA · Entity 6203	GrantCommon Stock	31,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-003241 · doc4.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of Issuer's common stock. 50% of the shares vest on January 10, 2021 and 1/24th of the shares vest monthly thereafter. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document
January 09, 2020 Filed Jan 13, 2020 20:35 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantStock Option (right to buy) · Derivative	19,675	$0.00 Strike: $6.87	$0.00	Disclosure SEC source: 0001683168-20-000108 · ownership.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,275 Underlying: Common Stock · 19,675 shares Expires 2027-01-09 F1 · shares: Annual grant of stock options pursuant to the Issuer's non-employee director compensation program. F2 · derivative.exercise_date: This option fully vests one year from the date of grant. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $53.61	$0.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · derivative · entry 12 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $45.64	$0.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · derivative · entry 11 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionStock Option (right to buy) · Derivative	22,500	$0.00 Strike: $40.65	$0.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · derivative · entry 10 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $41.36	$0.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · derivative · entry 9 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $17.81	$0.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · derivative · entry 8 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. F3 · derivative.expiration_date: Each option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00 (less the exercise price per share attributable to such Company Option), multiplied by the total number of shares of Company Common Stock issuable upon exercise in full of such Company Option, provided that if the exercise price per share of any such Company Option was equal to or greater than $60.00, such Company Option was cancelled for no consideration. The Company Options reported herein were canceled in the merger in exchange for a cash payment of $60.00 per share subject to such Company Option. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	SaleCommon Stock	165,925	$60.00	$9,955,500.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · nonDerivative · entry 7 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Disposed of for $60.00 per share pursuant to the terms of that certain Agreement and Plan of Merger dated as of August 7, 2019, by and among Catalog Intermediate Inc. ("Parent"), Catalog Merger Sub ("Merger Sub"), each entities controlled by investment funds advised by Permira Advisors LLC, and the Company (the "Merger Agreement"). All terms capitalized but not defined shall have the respective meanings given to them in the Merger Agreement. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	GrantCommon Stock	43,500	$0.00	$0.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · nonDerivative · entry 6 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,925 F1 · shares: Each Company restricted stock unit subject to performance-vesting conditions (each, a "Company PSU") that was outstanding immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash, without interest thereon, equal to the product of $60.00, multiplied by the total number of shares of Company Common Stock subject to such Company PSU, with any performance-based vesting conditions deemed achieved at the greater of (x) target levels of performance and (y) actual levels of performance, without pro-ration. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionCommon Stock	20,000	$53.61	$1,072,100.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · nonDerivative · entry 5 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionCommon Stock	25,000	$45.64	$1,140,875.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · nonDerivative · entry 4 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionCommon Stock	22,500	$40.65	$914,625.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · nonDerivative · entry 3 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionCommon Stock	15,000	$41.36	$620,400.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · nonDerivative · entry 2 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 04, 2019 Filed Dec 5, 2019 13:42 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionCommon Stock	7,500	$17.81	$133,575.00	Disclosure SEC source: 0001209191-19-059248 · doc4.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2019 Filed Feb 19, 2019 17:07 UTC	CAMBREX CORP CBM · Entity 153359	SaleCommon Stock	5,802	$37.45	$217,284.90	Disclosure SEC source: 0001209191-19-011184 · doc4.xml · nonDerivative · entry 2 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,425 F2 · shares: Broker-assisted sale of 5,802 shares to cover the payment of withholding tax liability from the settlement of a performance share award. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.32 to $37.57 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. Read SEC document
February 15, 2019 Filed Feb 19, 2019 17:07 UTC	CAMBREX CORP CBM · Entity 153359	GrantCommon Stock	12,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-011184 · doc4.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · CFO & EVP, Corp. Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,227 F1 · shares: Pursuant to settlement of a performance share award. Read SEC document
January 31, 2019 Filed Feb 4, 2019 18:27 UTC	CAMBREX CORP CBM · Entity 153359	GrantCommon Stock	6,227	$0.00	$0.00	Disclosure SEC source: 0001209191-19-006988 · doc4.xml · nonDerivative · entry 1 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,227 F1 · security: Represents Restricted Stock Units Read SEC document
December 14, 2018 Filed Dec 18, 2018 20:24 UTC	Avid Bioservices, Inc. CDMO · Entity 83494	GrantStock Option (right to buy) · Derivative	19,600	$0.00 Strike: $5.22	$0.00	Disclosure SEC source: 0001683168-18-003746 · ownership.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,600 Underlying: Common Stock · 19,600 shares Expires 2025-12-14 F1 · derivative.exercise_date: This option fully vests one year from the date of grant. Read SEC document
October 24, 2018 Filed Oct 26, 2018 16:09 UTC	CAMBREX CORP CBM · Entity 153359	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $53.61	$0.00	Disclosure SEC source: 0001209191-18-056288 · doc4.xml · derivative · entry 1 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-10-24 F1 · derivative.exercise_date: The option representing a right to purchase 20,000 shares becomes exercisable in four equal installments beginning October 24, 2019, which is the first anniversary of the date on which the option was granted. Read SEC document
May 08, 2018 Filed May 9, 2018 16:24 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $40.65	$0.00	Disclosure SEC source: 0001209191-18-028866 · doc4.xml · derivative · entry 12 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2023-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 26, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document
May 08, 2018 Filed May 9, 2018 16:24 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $41.36	$0.00	Disclosure SEC source: 0001209191-18-028866 · doc4.xml · derivative · entry 11 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2022-10-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2016, which was the first anniversary of the date on which the option was granted. Read SEC document
May 08, 2018 Filed May 9, 2018 16:24 UTC	CAMBREX CORP CBM · Entity 153359	Exercise / conversionStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $17.81	$0.00	Disclosure SEC source: 0001209191-18-028866 · doc4.xml · derivative · entry 10 SARGEN GREGORY · CIK 0001227835 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2021-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.